Deferasirox : a review of its use in the management of transfusional chronic iron overload.

Deferasirox : a review of its use in the management of transfusional chronic iron overload. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Deferasirox : a review of its use in the management of transfusional chronic iron overload. Abstract Text:

Lily P H Yang,Susan J Keam,Gillian M Keating,Lily P H Yang,Susan J Keam,Gillian M Keating,Lily P H Yang,Susan J Keam,Gillian M Keating,Lily P H Yang,Susan J Keam,Gillian M Keating,

Deferasirox (Exjade) is an oral, once-daily iron chelator widely approved for the treatment of transfusional chronic iron overload. In the EU, deferasirox is indicated in patients with beta-thalassaemia major aged > or =6 years and, in the US, in all transfusional chronic iron overload patients aged > or =2 years. Deferasirox is highly selective for iron as Fe3+. In approximately 1-year clinical trials of patients with transfusional chronic iron overload associated with beta-thalassaemia, sickle cell disease, myelodysplastic syndrome or other rare chronic anaemias, deferasirox 20 or 30 mg/kg/day had a beneficial effect on liver iron concentrations (LIC) and serum ferritin levels; tolerability issues were clinically manageable with regular patient monitoring. Although longer-term efficacy and tolerability data are required, in particular examining the prevention of iron overload-related complications and the effect of deferasirox on renal function, deferasirox is an easily administered iron chelator and is a valuable option in the management of transfusional chronic iron overload.

Deferasirox : a review of its use in the management of transfusional chronic iron overload. Publishing Authors By Initials

LP Yang,SJ Keam,GM Keating,LP Yang,SJ Keam,GM Keating,LP Yang,SJ Keam,GM Keating,LP Yang,SJ Keam,GM Keating,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Deferasirox : a review of its use in the management of transfusional chronic iron overload. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Drugs

VOLUME: 67

Page Numbers: 2211-30

Journal Abbreviation: Drugs

ISSN: 0012-6667

DAY: 11

MONTH: 10

YEAR: 2007

Deferasirox : a review of its use in the management of transfusional chronic iron overload. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7600076

Deferasirox : a review of its use in the management of transfusional chronic iron overload. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Deferasirox : a review of its use in the management of transfusional chronic iron overload. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Deferasirox : a review of its use in the management of transfusional chronic iron overload.

AFFILIATION: Wolters Kluwer Health | Adis, Auckland, New Zealand. demail@adis.co.nz

Country: New Zealand

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Drugs

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Deferasirox : a review of its use in the management of transfusional chronic iron overload Related Publications

• Activin-betaA signaling is required for zebrafish fin regeneration.
• Campuses of the LACC.
• Celecoxib : a review of its use in the management of arthritis and acute pain.
• Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment.
• Colesevelam: a review of its use in hypercholesterolemia.
• Computing van der Waals energies in the context of the rotamer approximation.
• Coupling molecular beacons to barcoded metal nanowires for multiplexed, sealed chamber DNA bioassays.
• Coverage and prior authorization of psychotropic drugs under Medicare Part D.
• Deferasirox : a review of its use in the management of transfusional chronic iron overload.
• Differences in hospice care between home and institutional settings.
• Distance-dependent emission from dye-labeled oligonucleotides on striped Au/Ag nanowires: effect of secondary structure and hybridization efficiency.
• Dr. Tom Lawrence: a life in chiropractic.
• E14 Therapy for CLL: current approach, future trends.
• Gene expression analysis of zebrafish heart regeneration.
• Maraviroc.
• Metallic barcodes for multiplexed bioassays.
• Methods for simulating the dynamics of complex biological processes.
• Modeling backbone flexibility to achieve sequence diversity: the design of novel alpha-helical ligands for Bcl-xL.
• Monoclonal antibodies in chronic lymphocytic leukemia.
• On-beam synchrony in the cerebellum as the mechanism for the timing and coordination of movement.
• One size doesn't fit all.
• Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair.
• Quantification of the neurotoxic beta-carboline harmane in barbecued/grilled meat samples and correlation with level of doneness.
• Revision anterior cruciate ligament reconstruction: timing of surgery and the incidence of meniscal tears and degenerative change.
• Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type.
• Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease.
• Silica-coated, Au/Ag striped nanowires for bioanalysis.
• The Homewood influence in Canada and beyond.
• Transcriptional profiling of caudal fin regeneration in zebrafish.
• Using performance data to identify preferred hospitals.